Sickle cell drug mitapivat faces Long-Term safety check in small study
NCT ID NCT04610866
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times
Summary
This study looks at the long-term safety and tolerability of the drug mitapivat in adults with stable sickle cell disease. Participants, who previously benefited from mitapivat in an earlier study, take the drug twice daily for up to 48 weeks, with an option to continue for another 48 weeks. The goal is to monitor side effects and see if the drug remains safe over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can Co-Designed support help parents embrace sickle cell care?
- Can community hospitals in zambia master severe disease care?
- A Pocket-Sized coach for sickle cell: can an app turn Pill-Taking into a habit?
- Can a phone app keep teens on track with sickle cell treatment?
- A common amino acid may calm sickle cell pain crises — a trial puts it to the test
- A drug that protects the liver may make stem cell transplants safer for children with sickle cell disease